Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elenestinib DDI Study with Midazolam and Oral Contraceptives in Healthy Females
NCT07388511Phase 1Completed
- Sponsor
- Blueprint Medicines
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elenestinib, sponsored by Blueprint Medicines. Primary endpoints: Area under the concentration-time curve, from time 0 to the last observed non-zero concentration up to 27 days, Area under the concentration-time curve from time 0 extrapolated to infinity up to 27 days and 6 more. Started Feb 2026; status: completed.
02
Drugs
elenestinib
Beyond the preview
Go deeper on NCT07388511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388511.